First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Vividion Therapeutics, Inc.
Fate Therapeutics
Apollomics (Australia) Pty. Ltd.
Incyte Corporation